Aptose Biosciences (NASDAQ:APTO) (TSE:APS) issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03, Morningstar.com reports.
NASDAQ APTO opened at $2.00 on Friday. Aptose Biosciences has a twelve month low of $1.57 and a twelve month high of $4.55. The company has a current ratio of 5.93, a quick ratio of 5.93 and a debt-to-equity ratio of 0.09. The stock has a market cap of $98.47 million, a price-to-earnings ratio of -2.33 and a beta of 1.57.
In related news, Director Erich Platzer sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total value of $43,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Gregory K. Chow bought 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was acquired at an average cost of $1.75 per share, for a total transaction of $26,250.00. Following the completion of the purchase, the chief financial officer now directly owns 122,014 shares of the company’s stock, valued at $213,524.50. The disclosure for this purchase can be found here. Insiders have acquired 35,000 shares of company stock worth $63,750 in the last 90 days. Company insiders own 7.34% of the company’s stock.
Several research firms have recently issued reports on APTO. HC Wainwright set a $9.00 target price on Aptose Biosciences and gave the company a “buy” rating in a report on Friday, March 22nd. Zacks Investment Research lowered Aptose Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, March 26th. Roth Capital restated a “buy” rating on shares of Aptose Biosciences in a research report on Thursday, May 23rd. Finally, Royal Bank of Canada initiated coverage on Aptose Biosciences in a research report on Friday, March 1st. They set an “outperform” rating and a $6.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $5.75.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Recommended Story: Lock-Up Period Expiration
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.